August 15, 2026 11:22 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe | From guns to glamour: Former women Maoists walk the ramp in Chhattisgarh
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.